Financiere des Professionnels’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Financiere des Professionnels’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$259K	Hold	5,376	–	–	0.02%	289
2025 Q4	$222K	Buy	+5,376	New	+$216K	0.01%	288

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Financiere des Professionnels's KNSA Position: Q1 2026 in Review

Financiere des Professionnels held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 5,376 shares worth $259K. The position accounts for 0.02% of the portfolio, ranked #289.

Financiere des Professionnels first reported a position in KNSA in Q4 2025 and has held it in 2 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Financiere des Professionnels held 5,376 shares of Kiniksa Pharmaceuticals worth $259K as of Q1 2026.
Financiere des Professionnels left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
Kiniksa Pharmaceuticals made up 0.02% of Financiere des Professionnels's portfolio in Q1 2026, its #289 holding.
Financiere des Professionnels first reported a position in Kiniksa Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Financiere des Professionnels's 13F filing for Q1 2026, filed 6 May 2026.